These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 27072856)

  • 1. Use of Thrombopoietin-Receptor Agonist in CVID-Associated Immune Thrombocytopenia.
    Carrabba M; Barcellini W; Fabio G
    J Clin Immunol; 2016 Jul; 36(5):434-6. PubMed ID: 27072856
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune thrombocytopenic purpura--from agony to agonist.
    Schwartz RS
    N Engl J Med; 2007 Nov; 357(22):2299-301. PubMed ID: 18046034
    [No Abstract]   [Full Text] [Related]  

  • 3. Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center.
    González KJ; Zuluaga SO; DaRos CV; Rodríguez PP; Martí AC
    Ann Hematol; 2017 Mar; 96(3):507-508. PubMed ID: 27975127
    [No Abstract]   [Full Text] [Related]  

  • 4. Thrombopoietin-receptor agonists in children with immune thrombocytopenia.
    Neunert CE; Grace RF
    Lancet; 2015 Oct; 386(10004):1606-9. PubMed ID: 26231462
    [No Abstract]   [Full Text] [Related]  

  • 5. Eltrombopag for chronic immune thrombocytopenia.
    Milosevic I; Slade E; Drysdale H;
    Lancet; 2016 Jan; 387(10016):336. PubMed ID: 26842445
    [No Abstract]   [Full Text] [Related]  

  • 6. Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus.
    Magnano L; Enríquez H; Esteve J; Cervera R; Espinosa G
    J Rheumatol; 2014 Sep; 41(9):1895-6. PubMed ID: 25179983
    [No Abstract]   [Full Text] [Related]  

  • 7. Eltrombopag for chronic immune thrombocytopenia - Authors' reply.
    Grainger JD;
    Lancet; 2016 Jan; 387(10016):336-337. PubMed ID: 26842444
    [No Abstract]   [Full Text] [Related]  

  • 8. Eltrombopag--an oral thrombopoietin agonist.
    Sharma V; Randhawa H; Sharma A; Aggarwal S
    Eur Rev Med Pharmacol Sci; 2012 Jun; 16(6):743-6. PubMed ID: 22913204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eltrombopag in thrombocytopenia.
    Zimmer J; Hentges F; Andrès E
    N Engl J Med; 2008 Mar; 358(10):1072; author reply 1072-3. PubMed ID: 18326076
    [No Abstract]   [Full Text] [Related]  

  • 10. Thrombopoietin receptor agonists in immune thrombocytopenia of less than 6 months duration.
    Arumugaswamy A; He S; Quach H; Brotchie J; Grigg A
    Intern Med J; 2014 May; 44(5):519-21. PubMed ID: 24816314
    [No Abstract]   [Full Text] [Related]  

  • 11. Thrombopoietin-receptor agonist as a treatment of thrombocytopenia associated with systemic lupus erythematosus.
    Moreno Martínez MJ; Gallego P; Moreno Ramos MJ
    Reumatol Clin; 2016; 12(1):57. PubMed ID: 26024588
    [No Abstract]   [Full Text] [Related]  

  • 12. Sustaining platelet counts in chronic ITP.
    Nurden AT
    Lancet; 2011 Jan; 377(9763):358-60. PubMed ID: 20739056
    [No Abstract]   [Full Text] [Related]  

  • 13. What is publication? The case of eltrombopag.
    Benham L; Guo L; Turner R
    Lancet; 2011 Jan; 377(9763):360-1. PubMed ID: 21277427
    [No Abstract]   [Full Text] [Related]  

  • 14. [Development of thrombopoietin receptor agonists].
    Miyakawa Y
    Rinsho Ketsueki; 2009 Oct; 50(10):1434-43. PubMed ID: 19915352
    [No Abstract]   [Full Text] [Related]  

  • 15. Eltrombopag, a second-generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia-associated ITP.
    Koehrer S; Keating MJ; Wierda WG
    Leukemia; 2010 May; 24(5):1096-8. PubMed ID: 20339441
    [No Abstract]   [Full Text] [Related]  

  • 16. New therapy options for chronic immune thrombocytopenic purpura: a breath of fresh air. Introduction.
    Francesco R
    Eur J Haematol Suppl; 2009 Mar; (71):1-2. PubMed ID: 19200300
    [No Abstract]   [Full Text] [Related]  

  • 17. [Development of myelofibrosis during eltrombopag treatment in a patient with immune thrombocytopenia].
    Horikoshi A; Tsukuda J; Abe R; Fujiwara N; Ito E; Takaku T
    Rinsho Ketsueki; 2016 May; 57(5):638-41. PubMed ID: 27263792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombopoietin receptor agonists as an emergency treatment for severe newly diagnosed immune thrombocytopenia in children.
    Nolla M; Aladjidi N; Leblanc T; Fernandes H; Ducassou S; Fahd M; Barlogis V; Michel M; Blouin P; Jeziorski E; Benadiba J; Pondarre C; Leverger G; Pasquet M
    Blood; 2021 Jan; 137(1):138-141. PubMed ID: 33410895
    [No Abstract]   [Full Text] [Related]  

  • 19. [Thrombopoietin-receptor agonists: a revolution in the therapeutic strategies of immune thrombocytopenic purpura?].
    Godeau B;
    Rev Med Interne; 2009 Mar; 30(3):203-5. PubMed ID: 19019500
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
    Tsukamoto S; Nakaseko C; Takeuchi M; Kumagai K; Komatsu T; Tanaka H; Hara S; Koizumi M; Imai H; Yokota A; Takeuchi M; Inokuchi K; Matsuura Y; Aotsuka N; Wakita H
    Br J Haematol; 2013 Oct; 163(2):286-9. PubMed ID: 23862773
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.